Neurosense Therapeutics Files Form 6-K Neurosense filed a Form 6-K on Apr 3, 2026 (13:30:35 GMT). Institutional teams should verify primary sources and monitor a 72-hour window for follow-up disclosures.

Neurosense Therapeutics Files Form 6-K: Neurosense filed a Form 6-K on Apr 3, 2026 (13:30:35 GMT). Institutional teams should verify primary sources and monitor a 72-hour window for follow-up disclosures. 👈 Read full analysis #Neurosense #Therapeutics #Investing #FinanceNews #StockMarket

🚨 Just over one week left to apply to our second NeuroAdapt Fellowship call.

Join FutureNeuro and help advance cutting-edge research in #Diagnostics, #Therapeutics & #DigitalHealth for brain conditions.

Apply by 10 April: futureneurocentre.ie/neuroadapt/a...

@ec.europa.eu @researchireland.ie

Dr. Nathan Bryan interviews Nobel Prize winner Prof. Louis Ignarro

Discover what is next in medicine at NO2026.
no2026.com

#NO2026 #MedicalInnovation #Therapeutics #FutureOfMedicine #ScienceDriven #HealthcareEvolution

Dr. Nathan Bryan interviews Nobel Prize winner Prof. Louis Ignarro

Discover what is next in medicine at NO2026.
no2026.com

#NO2026 #MedicalInnovation #Therapeutics #FutureOfMedicine #ScienceDriven #HealthcareEvolution

Inhibikase Therapeutics Files Form 8-K on March 26 Inhibikase filed an SEC Form 8‑K on Mar 26, 2026; the SEC requires 8‑Ks within 4 business days — immediate EDGAR review is warranted.

Inhibikase Therapeutics Files Form 8-K on March 26: Inhibikase filed an SEC Form 8‑K on Mar 26, 2026; the SEC requires 8‑Ks within 4 business days — immediate EDGAR review is warranted. 👈 Read full analysis #Inhibikase #Therapeutics #SEC #Form8K #BusinessNews

Fresh Alzheimer’s theory gives investors new lens on why upstream biology may matter more in the race for durable longevity therapeutics.

Link as first comment.

#longevity #alzheimers #therapeutics #geroscience #biotech

Hematopoietic stem cell transplantation as a curative treatment for Nck-associated protein 1-like (HEM1) deficiency: A first case report. From Julian Thalhammer, Wadih Abou Chahla @chulille.bsky.social and colleagues: rupress.org/jhi/article/...

#InbornErrorsOfImmunity #Therapeutics #HSCT

Discovery of a Colon-Targeted Prodrug As an Escherichia coli Biofilm Inhibitor for Treating Inflammatory Bowel Disease We hypothesized that the formation of biofilms contributes to the onset of inflammatory bowel disease and, thus, attempted to develop biofilm inhibitors as potential treatment options. We identified a...

Discovery of a Colon-Targeted Prodrug as an Escherichia coli Biofilm Inhibitor for Treating Inflammatory Bowel Disease

pubs.acs.org/doi/10.1021/... @pubs.acs.org

#MedicinalChemistry #DrugDiscovery #ProdrugDesign #InflammatoryBowelDisease #Pharmacology #Therapeutics #GutHealth #DrugDevelopment

Design, Synthesis, and Characterization of Prodrugs of Sulfonamide TLR4 Signaling Inhibitor TAK-242 (Resatorvid) We have previously reported two prodrug designs for the delivery of the potent TLR4 inhibitor TAK-242. Our initial design was used to covalently link TAK-242 to pancreatic islets using a linker to afford sustained delivery of the active drug after transplant. Those drug-eluting islets provided local inhibition of TLR4-linked inflammation and improved islet graft survival. Here, we describe a third family of TAK-242 prodrugs featuring two rate modulating sites, a self-immolative aniline-stabilized methylene spacer bonded directly to the sulfonamide nitrogen, an alcohol tether for bioconjugation, and a β-eliminative aryl-sulfone “trigger”. These prodrugs rapidly release TAK-242 after activation by β-elimination and a rapid subsequent 1,2-elimination, cleanly releasing the drug without detectable intermediates. This manuscript reports the preparation and characterization of a series of methylene-linked TAK-242 prodrugs, evaluating the impact of various modifications on drug release kinetics.

Design, Synthesis, and Characterization of Prodrugs of Sulfonamide TLR4 Signaling Inhibitor TAK-242 (Resatorvid) pubs.acs.org/doi/10.1021/... @pubs.acs.org

#MedicinalChemistry #DrugDesign #ProdrugStrategy #InflammationResearch #Immunology #Pharmacokinetics #Therapeutics #DrugDevelopment

🚨 New funding for infectious disease research

New call for developing randomised controlled trials to optimise existing #vaccines and #therapeutics for infectious diseases.

📆 Apply by 2 June 2026.

🔗 More: wellcome.org/research-fun...

@wellcometrust.bsky.social @nihr.bsky.social

American Society for Clinical Pharmacology & Therapeutics podcast: Understudied populations - a call for papers Listen Now

Clinical Pharmacology & Therapeutics is publishing a themed issue on understudied populations.

Listen to the latest ASCPT podcast and find out what editors are looking to publish!

Submit by June 30: https://ow.ly/24LR50YtLyt

#ClinicalPharmacology #HealthEquity #Therapeutics #DrugDevelopment

Join the CARB-X team for public webinars to learn more about the 2026 funding round, seeking #preventatives, #therapeutics, and #diagnostics to address AMR. #IDSky #ChemSky 🧪
📆 9 April at 17:30 ET
🔗 Register: bit.ly/4aPGbWR

📆 10 April at 09:00 ET
🔗 Register: bit.ly/4u8u6DR

🚨 Just one month left to apply for our second NeuroAdapt MSCA Fellowship!

Join FutureNeuro and help advance cutting-edge research in #Diagnostics, #Therapeutics, and #DigitalHealth for brain conditions.

👉 Apply by 10 April: futureneurocentre.ie/neuroadapt/a...

🎓 Trainees & Young Investigators: Funding is available to attend the 18th Int'l Conference on #Complement #Therapeutics May 27–June 1, 2026 Sissi, Crete 🇬🇷
📢 Submit your abstract and join us!
🔗 www.aegeanconferences.org/src/App/conf...
#ComplementTherapeutics #EarlyCareerResearchers #Immunology

Deal aimed at developing therapy to fight toxic protein in ALS... Transition Bio and Voyager have teamed to discover and develop new small molecules that target toxic TDP-43 protein clumps in ALS and FTD.

A new research deal is targeting toxic proteins behind #ALS and #FTD — a hopeful advance in developing therapies that go after the disease mechanisms. 🧬

Read more: https://ow.ly/XsTV50Ym5cx

#NeurodegenerativeDisease #MedicalResearch #Therapeutics #Biotech #HealthNews

Hematopoietic stem cell transplant with a carrier donor rescues CD40L deficiency. New case report from Christen L. Ebens @umnpeds.bsky.social, Amir A. Sadighi Akha @mayoclinic.org and colleagues: rupress.org/jhi/article/...

#InbornErrorsOfImmunity #Therapeutics #HSCT

Funds are still available for Trainee & Young Investigator Travel Awards!
Apply by Feb 28 for the 18th Int'l Conference on #Complement #Therapeutics
📅 05/27/2026 – 06/01/2026
📍 #Sissi, #Crete, #Greece
🏛 #KalimeraKriti Conference Center
Apply here:
aegeanconferences.org/src/App/page...

#BPS2026 Newsroom Spotlight - Sometimes Less is More: Scientists Rethink How to Pack Medicine into Tiny Delivery Capsules @nhalzakis @ucph_research #mRNA #vaccines #therapeutics #cancertreatment

Original post on mastodon.online

Single Dose of DMT Rapidly Reduces Symptoms of Major Depression

Small Phase IIa study [34 subjects] but some interesting points
"intravenous DMT has a half-life of around five minute"
and
"A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive […]

Comprehensive Physiology | Review Spotlight 🔦 This 2025 review highlights T2DM causes, comorbidities, and new therapies, plus a roadmap for future drug discovery. Read: https://ow.ly/R18750YcmSW #Type2Diabetes #DiabetesResearch #Physiology #Therapeutics #HealthyLifestyle

Karyopharm Therapeutics Announces 2025 Financial Results and Key Milestones Ahead Karyopharm Therapeutics has shared its financial results for 2025, highlighting growth, product performance, and key upcoming trials set for 2026.

Karyopharm Therapeutics Announces 2025 Financial Results and Key Milestones Ahead #United_States #Karyopharm #XPOVIO #Newton #Therapeutics

Anticodon-edited transfer RNAs (ACE-tRNAs) encoded as therapeutic nonviral minimal DNA vectors Abstract. Nonsense mutations, resulting from a premature termination codon (PTC), make up ∼11% of all genetic lesions causing disease, affecting millions o

Excited for our most recent study that does a deep dive into therapeutic minivectors that express ACE-tRNAs for treatment of nonsense-associated diseases. The method development here was years in the making. Check it out at NAR! #nonsense #tRNAs #therapeutics #NAR

doi.org/10.1093/nar/...

Targeting tau in #AlzheimersDisease: rationale, approach and challenges

Aram Aslanyan, Martha S. Foiani, Tatiana A. Giovannucci...Ross W. Paterson @ukdri.ac.uk #biomarkers #therapeutics

link.springer.com/article/10.1...

Abstract Submission, Travel Award Applications, and Early Fee Deadline Extended to February 28. Join us at the 18th Int'l Conference on #Complement #Therapeutics www.aegeanconferences.org/src/App/conf... #Crete #Greece May 27-June 1, 2026 #ComplementTherapeutics

Today is #WorldNeglectedTropicalDiseasesDay. We stand with the #WHO to Unite, Act, Eliminate. New #therapeutics are an essential part of achieving this.

www.who.int/campaigns/wo...

Green synthesis of alginate-encapsulated silver nanoparticles and its utilization as anticancer and antimicrobial therapeutics

Scientists develop green-synthesized alginate-encapsulated #AgNPs from C. fistula that show dual #anticancer and #antimicrobial activity, highlighting their promise as multitargeted #therapeutics for #cancer and #MicrobialDiseases.
Nanotechnology Reviews: doi.org/10.1515/ntre...

DUB Inhibitors Market Expected to Experience Significant Growth by 2040 with Innovative Therapeutics Advancements The DUB inhibitors market is set for remarkable growth driven by innovative therapies targeting cancer and neurodegenerative diseases. Insights from key trends and market forecasts reveal future opportunities.

DUB Inhibitors Market Expected to Experience Significant Growth by 2040 with Innovative Therapeutics Advancements #None #oncology #Therapeutics #DUB_inhibitors

Halozyme Therapeutics Increases Revenue Estimates Through 2025 and Beyond with New Acquisition Halozyme Therapeutics has raised its revenue estimates for 2025 and set ambitious financial guidance for 2026, driven by innovative acquisitions and strong royalty growth.

Halozyme Therapeutics Increases Revenue Estimates Through 2025 and Beyond with New Acquisition #United_States #San_Diego #Halozyme #Therapeutics #ENHANZE

Check out the 2024 edition on the latest research into Antiphospholipid Syndrome (APS), a rare autoimmune disease that causes the blood to clot.

" #Researchers are still trying to understand the full role of β2GPI as well as #AntiphospholipidSyndrome. So whilst these #therapeutics sound exciting, it will probably still be many years before we see them in practice.": buff.ly/r5TlLCA

#MedSky #ChronicIllness

Impact of Kellgren–Lawrence grade on clinical outcomes following adipose-derived stem cell therapy for knee osteoarthritis: A propensity score–matched retrospective cohort study
@celltransplant1992.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#regeneration #therapeutics